Media ReleasesSomnomed Limited

View All Somnomed Limited News


SomnoMed Investor Presentation - Half Year Review Financial Year 2015-2016

Global highlights first half 2015/16
 
-  Direct sales volumes +28.8% and group revenues +30.2%
 
-  MAS gross margin maintained at 68.5% and Group gross margin up to 57.5%
 
-  Licensee sales now less than 10% of North American sales
 
-  EBITDA up 124% to $908,000
 
-  Acquisition of remaining 50% of SMH Biomaterials AG
 
-  Acquisition of Strong Dental Canada
 
-  Transition to digital scanning underway
 
-  New clinical research published confirming medical efficacy and high compliance  of COAT 
 
 
To view Presentation please download PDF attached:
Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?